Compare · LITS vs VKTX
LITS vs VKTX
Side-by-side comparison of Lite Strategy Inc. (LITS) and Viking Therapeutics Inc. (VKTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LITS and VKTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- VKTX is the larger of the two at $3.30B, about 131.7x LITS ($25.0M).
- LITS has been more active in the news (10 items in the past 4 weeks vs 7 for VKTX).
- VKTX has more recent analyst coverage (24 ratings vs 0 for LITS).
- Company
- Lite Strategy Inc.
- Viking Therapeutics Inc.
- Price
- -
- -
- Market cap
- $25.0M
- $3.30B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2003
- 2015
- News (4w)
- 10
- 7
- Recent ratings
- 0
- 24
Viking Therapeutics Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃ for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Latest LITS
- Director Charles Benjamin Lee exercised 517,509 shares at a strike of $0.00 and covered exercise/tax liability with 44 shares (SEC Form 4)
- Director James P Flynn bought $21,548 worth of shares (27,450 units at $0.79), increasing direct ownership by 22% to 152,450 units (SEC Form 4)
- Lite Strategy Reports Fiscal 2027 First Quarter Financial Results
- SEC Form 10-Q filed by Lite Strategy Inc.
- Lite Strategy Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- Director Glover Nicholas bought $12,550 worth of shares (2,000 units at $6.28) (SEC Form 4)
- SEC Form 4 filed by Lite Strategy Inc.
- SEC Form 4 filed by Lite Strategy Inc.
- SEC Form 4 filed by Lite Strategy Inc.
- SEC Form 4 filed by Lite Strategy Inc.
Latest VKTX
- Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
- Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Viking Therapeutics Inc.
- Viking Therapeutics to Participate at Upcoming Investor Conferences
- SEC Form 10-Q filed by Viking Therapeutics Inc.
- SEC Form 8-K filed by Viking Therapeutics Inc.
- Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
- UBS initiated coverage on Viking Therapeutics with a new price target
- Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity